Reactogenicity and immunogenicity profile of a two-dose combined hepatitis A and B vaccine in 1–11-year-old children
| Autor: | Javier Díez-Domingo, D Van Esso, Don Roberton, Michel Stoffel, Helen Marshall, J Verdaguer, C-E Flodmark, Ilse Dieussaert, J Marés, G Lewald, Lars Rombo, J de la Flor, Etienne Sokal, Terry Nolan, J.M. Casanovas |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
HBsAg
Pediatrics medicine.medical_specialty Hepatitis A vaccine Drug Administration Schedule children medicine Humans Hepatitis B Vaccines Vaccines Combined Seroconversion Child Immunization Schedule combined vaccine Hepatitis Hepatitis A Vaccines Reactogenicity General Veterinary General Immunology and Microbiology business.industry Public Health Environmental and Occupational Health Infant Hepatitis A Hepatitis B hepatitis A and B medicine.disease Vaccination Infectious Diseases Child Preschool Immunology Molecular Medicine business |
| Zdroj: | Vaccine r-FISABIO: Repositorio Institucional de Producción Científica Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) r-FISABIO. Repositorio Institucional de Producción Científica instname |
| ISSN: | 0264-410X 1358-8745 |
| DOI: | 10.1016/j.vaccine.2005.06.003 |
| Popis: | This study was conducted to compare the reactogenicity, immunogenicity and safety of a combined two-dose (0, 6 months) hepatitis A and B vaccine (720 EL U HAV, 20 mcg HBsAg) with the established three-dose (0, 1 and 6 months) hepatitis A and B vaccine (360 EL U HAV, 10 mcg HBsAg). A total of 511 children aged 1-11 years who had not previously received a hepatitis A or B vaccine were enrolled in the study. Both vaccines were well tolerated, and were shown to be safe and immunogenic. The analysis, stratified according to two age groups (1-5 year and 6-11-year-old children) demonstrated that the reactogenicity profile of the two-dose schedule was at least as good as that of the established schedule. Both vaccines and schedules provided at least 98% seroprotection against hepatitis B and 100% seroconversion against hepatitis A, I month after the end of the vaccination course (Month 7). (c) 2005 Elsevier Ltd. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect